5 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group

In this article, we discuss the 5 pharmaceutical stocks to buy under $20 according to Jeremy Green’s Redmile Group portfolio based on Q3 holdings of the fund. If you want to read our detailed analysis of Green’s history, investment philosophy, and hedge fund performance, go directly to the 10 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group.

5. Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Redmile Group Stake Value: $198,633,000
Percentage of Redmile Group’s 13F Portfolio: 3.46%
Number of Hedge Fund Holders: 31
Price per Share as of Nov. 23, 2021: $11.24

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotech company focused on developing medicinal treatments for rare metabolic illnesses. According to the most recent 13F filings, Perceptive Advisors is the largest investor in Amicus Therapeutics, Inc. as of the third quarter of 2021, with 26.56 million shares valued at more than $253.64 million.

On November 15, Stifel analyst Dae Gon Ha upgraded Amicus Therapeutics to “Buy” from “Hold” with a price target of $16, up from $12.

Amicus Therapeutics, Inc. was owned by 31 hedge funds out of the 867 funds tracked by Insider Monkey in the third quarter of 2021, down from 34 the previous quarter. These holdings are worth a total of $833.72 million.

In its first-quarter 2021 investment letter, Carillon Tower Advisers mentioned Amicus Therapeutics, Inc. (NASDAQ: FOLD). Here is what it said:

“Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. The firm’s shares slumped after it reported disappointing results in the phase three trial for its drug to be used in the treatment of late-onset Pompe disease (LOPD). Unfortunately, the trial data did not generate statistical significance in the primary endpoint.”